Randomised control trial of HG therapy
A longer-term aim of the HGF is the organisation of a randomised control trial (RCT) of HG therapy. It has been recognised for some time that the absence of such a study is a barrier to official recognition of the approach, including its inclusion in NICE guidelines. In 2016, the NIHR (National Institute for Health Research) in 2016 turned down the HGF’s bid for funding to carry out an RCT feasibility study. The Trustees will continue to explore options in relation to an RCT.